New hope for tough-to-treat myeloma: combo therapy targets tumors outside bones

NCT ID NCT04166565

Ongoing Disease control Sponsor: Stichting European Myeloma Network Source: ClinicalTrials.gov ↗

First seen May 01, 2026 · Last updated May 24, 2026 · Updated 5 times

Summary

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread outside the bones (extramedullary disease). The goal is to see if this stronger treatment can shrink or control these hard-to-treat tumors. Participants are either newly diagnosed or have had only one prior treatment, and they will be followed for up to 5 years to monitor response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Ankara University

Ankara, Turkey (Türkiye)
Anticancer Hospital of Thessaloniki

Thessaloniki, Greece
Dokuz Eylul University

Balçova, Turkey (Türkiye)
Erciyes University

Kayseri, Turkey (Türkiye)
Marmara University

Pendik, Turkey (Türkiye)
Univerity of Turin

Torino, Italy
University of Athens

Athens, Greece
University of Bologna

Bologna, Italy

Conditions

Explore the condition pages connected to this study.

EXTRAMEDULLARY PLASMACYTOMA MULTIPLE MYELOMA